WO1997017078A1 - Utilisation de polyethyleneglycol pour assurer la prophylaxie ou le traitement d'affections des muqueuses - Google Patents

Utilisation de polyethyleneglycol pour assurer la prophylaxie ou le traitement d'affections des muqueuses Download PDF

Info

Publication number
WO1997017078A1
WO1997017078A1 PCT/EP1996/004890 EP9604890W WO9717078A1 WO 1997017078 A1 WO1997017078 A1 WO 1997017078A1 EP 9604890 W EP9604890 W EP 9604890W WO 9717078 A1 WO9717078 A1 WO 9717078A1
Authority
WO
WIPO (PCT)
Prior art keywords
use according
mixture
polyethylene glycol
prostaglandins
mucous membranes
Prior art date
Application number
PCT/EP1996/004890
Other languages
German (de)
English (en)
Inventor
Christian Bannert
Original Assignee
Christian Bannert
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Christian Bannert filed Critical Christian Bannert
Publication of WO1997017078A1 publication Critical patent/WO1997017078A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Definitions

  • polyethylene glycol for the prevention or treatment of diseases of the mucous membranes
  • the present invention relates to the use of polyethylene glycol or mixtures containing polyethylene glycol for the prevention or / and treatment of radiation and / or chemotherapy-induced diseases of the mucous membranes.
  • Inflammation of the oral mucosa often occurs as a side effect of the therapy in these patients.
  • chemotherapeutic agents e.g. 5-fluorouracil, bleomycin, cis and carboplatin, doxyrubicin and analogues, methotrexate and vinblastine
  • large-scale inflammatory infiltrations of the entire oral mucosa and desquamation of parts of the mucous membrane can occur, which is associated with severe pain.
  • the lips open, bleed and hurt badly.
  • Known methods of treatment are local applications of liquid pharmaceutical preparations with local anesthetics, such as lidocaine, with disinfectants such as chlorhexidine and with antifungals such as amphotericin B.
  • local anesthetics such as lidocaine
  • disinfectants such as chlorhexidine
  • antifungals such as amphotericin B.
  • mouthwash solutions or herbal teas or moisturizers such as e.g. Saliva replacement solutions and salt solutions to be used for treatment.
  • these methods only partially reduce mucositis, stomatitis or oral infection. The detachment of viscous secretions from the oral mucosa is also insufficient with these methods.
  • the viscous mucus must first be removed before other local therapeutic measures can be initiated.
  • Known medicinal pharmaceutical measures to reduce the viscous slime formation are rinses with water, tea, salt solutions, such as the commercial product Emser salt ®, with disinfectants such as the drug Hexoral ®, with speichel ⁇ -dissolving enzymes such as lysozyme, having means for Reduction of surface activity such as glycyrrhizic acid, with saliva replacement solutions such as the drug Glandosane ® and systemic agents such as acetylcysteine, bromhexine and ambroxol.
  • the object of the invention was therefore to provide a means by which the disadvantages of the prior art are at least partially eliminated.
  • the object is achieved according to the invention by using polyethylene glycol or mixtures containing polyethylene glycol for the prevention and / or treatment of radiation and / or chemotherapy-induced diseases of the mucous membranes, in particular the mucous membrane of the aerodigestive tract.
  • polyethylene glycol or mixtures containing polyethylene glycol are able to remove the viscous mucus quickly and satisfactorily from the oral mucosa, improve oral hygiene and alleviate the subjective complaints associated with viscous mucus formation .
  • An aqueous polyethylene glycol mixture is preferably used according to the invention.
  • any polyethylene glycols can be used according to the invention.
  • Polyethylene glycols with an average molecular weight of 200 to 6000 and particularly preferably with an average molecular weight of 300 to 1500 are preferably used.
  • the polyethylene glycols used according to the invention are mixtures of polymers of ethylene oxide. The characteristic number indicates the approximate average molecular weight of the polyethylene glycols, which become increasingly viscous with increasing molecular weight.
  • a mixture is preferably used according to the invention which contains prostaglandins in addition to polyethylene glycol.
  • two therapy goals are met, namely the detachment of the viscous secretion from the oral mucosa by the polyethylene glycol portion and the other a healing effect based on the prostaglandins. Only after cleaning the oral mucosa from viscous secretion using polyethylene glycol, the prostaglandin can achieve its full effectiveness even in low concentrations.
  • an anhydrous mixture of polyethylene glycol and prostaglandins has a longer shelf life than aqueous solutions of prostaglandins, as a result of which longer storage and distribution as pharmaceuticals are possible.
  • these products should be protected from light and stored in a cool place.
  • suitable antioxidants e.g. Chelating agents and olefin oxides are added.
  • Prostaglandins such as Alprostadil and Dinoproston are generally only short-lived in an aqueous environment, i.e. Can be stored for a maximum of 1 week at 4 ° C and pH ⁇ 7.
  • the water-free, polyethylene glycol-prostaglandin mixture according to the invention can, if necessary, be mixed with water before use.
  • a polyethylene glycol-prostaglandin mixture preferred according to the invention preferably contains 0.01 mg% to 100 mg% prostaglandins, particularly preferably 0.1 mg% to 10 mg% prostaglandins and most preferably about 1 mg% prostaglanins dine (mg% here means mg in 100 g).
  • prostaglandins with a healing effect in inflammation are used, preferably the prostaglandins alprostadil and / or dinoprostone.
  • the mixture used according to the invention can also preferably contain a surface anesthetic or / and an antifungal.
  • the surface anesthetic or / and the antifungal are preferably present in a concentration of up to 10% by weight.
  • the surface anesthetic lidocaine base and / or the antifungal agent amphotericin B is particularly preferably used.
  • the mixture according to the invention is preferably applied to the lips or / and the mucous membrane.
  • the mixture can preferably be used for rinsing and dissolving viscous mucus, it preferably being used as an aqueous rinsing solution.
  • a solution can be prepared, for example, by dissolving 2 to 3 g of a polyethylene glycol-prostaglandin mixture in 50 ml of water.
  • Such a rinsing solution is then moved back and forth in the mouth for at least 1 minute and then spit out.
  • the rinsing solution can also be sprayed onto the mucous membrane or the viscous secretion.
  • Polyethylene glycols are physiologically safe and are used pharmaceutically as an ointment base, suppository mass and as a tablet component. Solutions of polyethylene glycol in water are used as a rinsing solution for detoxification and for colon cleansing before diagnostic examinations, such as for example Colonoscopy used. The physiological harmlessness of polyethylene glycols is also evident when using polyethylene glycol as a solubilizer for the active ingredient aluminum chlorate in the oral disinfectant Mallebrin ® , in which the content of polyethylene glycol in the intended application dilution is 100 mg%. Derivatives of polyethylene glycol are also usually contained in commercially available solutions for removing tooth plaque.
  • Prostaglandins of the prostaglandin E type in particular prostaglandin E1 (alprostadil) and prostaglandin E2 (dinoprostone) and their derivatives, analogs, physiologically tolerable salts, esters, amides, phospholipids and / or glycolipids are preferably used according to the invention.
  • the curative effect in mucositis is probably due to the vasodilating and circulation-enhancing properties of the prostaglandins.
  • the invention further comprises the use of a medicament which contains polyethylene glycol or a mixture containing polyethylene glycol for the prevention or / and treatment of diseases of the mucous membranes, and a method for producing this medicament.
  • the anhydrous mixtures according to example la) and lb) can be used directly, e.g. can be used as a rinsing solution by application to the lips or the mucous membrane, or after dilution with water.
  • aqueous pure dinoprostone mouth spray that did not contain polyethylene glycol and dinoprostone in a concentration of 0.5 mg%. Clinical results similar to those obtained with the 5 mg% dinoprostone solution were obtained. The effect was all the better, the more the patients practiced consistent oral care by rinsing with saliva substitute solutions or teas.
  • the aqueous pure dinoprostone mouth sprays however, have a very short shelf life and must be applied as a cooled solution.
  • stage 0 no changes in the oral mucosa
  • stage I erythema, soreness
  • stage II erythema, ulcers
  • patient can eat solid foods
  • stage III ulcers
  • the patient only tolerates liquid food
  • stage IV the patient cannot take any food orally, neither liquid nor solid.
  • the subjective complaints of the patients were also significantly reduced using the polyethylene glycol / dinoprostone mixture according to the invention. Difficulties in speaking and swallowing, foreign body sensation in the throat, swollen tongue, sticking of the tongue to the palate, unpleasant taste in the mouth, and burning and pain in the mouth were significantly reduced.
  • the polyethylene glycol-dinoprostone mixtures according to the invention were used in patients who were treated with chemotherapeutic agents.
  • V Vepesid (etoposide)
  • I Iphosphamide
  • C Carboplatin
  • E Epirubicin
  • BEAM (B BCNU (Carmustine)
  • E Etoposide
  • A ARAC (Cytabarin)
  • M Melphalan

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne l'utilisation de polyéthylèneglycol ou de mélanges contenant du polyéthylèneglycol, utilisés pour assurer la prophylaxie et/ou le traitement d'affections des muqueuses, induites par radio- et/ou chimiothérapie, notamment d'affections de la muqueuse de la voie aéro-digestive.
PCT/EP1996/004890 1995-11-09 1996-11-07 Utilisation de polyethyleneglycol pour assurer la prophylaxie ou le traitement d'affections des muqueuses WO1997017078A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19541815.8 1995-11-09
DE19541815A DE19541815B4 (de) 1995-11-09 1995-11-09 Verwendung einer Lösung von Polyethylenglykol in Wasser als wässrige Spüllösung zur Prävention oder Behandlung von zähem Schleim, der in Verbindung mit Strahlen- oder/und Chemotherapie-induzierten Erkrankungen der Schleimhäute auftritt

Publications (1)

Publication Number Publication Date
WO1997017078A1 true WO1997017078A1 (fr) 1997-05-15

Family

ID=7777045

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1996/004890 WO1997017078A1 (fr) 1995-11-09 1996-11-07 Utilisation de polyethyleneglycol pour assurer la prophylaxie ou le traitement d'affections des muqueuses

Country Status (2)

Country Link
DE (1) DE19541815B4 (fr)
WO (1) WO1997017078A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291500B2 (en) * 1997-10-22 2001-09-18 Jens Ponikau Methods and materials for treating and preventing inflammation of mucosal tissue
EP1744767A2 (fr) * 2004-04-20 2007-01-24 The University of Chicago Systeme d'administration therapeutique comprenant un compose de type peg de poids moleculaire eleve

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS53139716A (en) * 1977-05-12 1978-12-06 Sankyo Co Ltd Pharmaceutical preparation of stable prostaglandine
EP0103290A2 (fr) * 1982-09-14 1984-03-21 Intermedicat Gmbh Compositions pharmaceutiques pour le traitement de coalescence indésirable et leur utilisation
JPH0725769A (ja) * 1992-10-20 1995-01-27 Fuji Chem Ind Co Ltd アロプリノール医薬用液剤ならびにその製造法
RU2033789C1 (ru) * 1992-07-20 1995-04-30 Акционерное общество "НИЗАР" Биологически активное вещество косметических средств, стимулирующее процессы обмена веществ в покровных тканях

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5112620A (en) * 1990-09-20 1992-05-12 Mikkur, Inc. Polyethylene glycol ointment for apthous ulcers
JPH07508975A (ja) * 1992-04-23 1995-10-05 バーレックス　ラボラトリーズ　インコーポレイテッド 生体接着性水性鉱油エマルション軟膏基剤，それからなる局所医薬組成物及び創傷治癒におけるその使用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS53139716A (en) * 1977-05-12 1978-12-06 Sankyo Co Ltd Pharmaceutical preparation of stable prostaglandine
EP0103290A2 (fr) * 1982-09-14 1984-03-21 Intermedicat Gmbh Compositions pharmaceutiques pour le traitement de coalescence indésirable et leur utilisation
RU2033789C1 (ru) * 1992-07-20 1995-04-30 Акционерное общество "НИЗАР" Биологически активное вещество косметических средств, стимулирующее процессы обмена веществ в покровных тканях
JPH0725769A (ja) * 1992-10-20 1995-01-27 Fuji Chem Ind Co Ltd アロプリノール医薬用液剤ならびにその製造法

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
C. GUTURIEZ-CABANO: "Intragastric polyethylene glycol-400...", DIGESTIVE DISEASES AND SCIENCES, vol. 40, no. 9, September 1995 (1995-09-01), pages 2029 - 36, XP000650844 *
DATABASE WPI Section Ch Week 7903, Derwent World Patents Index; Class A96, AN 78-87252A, XP002025212 *
DATABASE WPI Section Ch Week 9514, Derwent World Patents Index; Class A96, AN 95-101798, XP002025213 *
DATABASE WPI Section Ch Week 9601, Derwent World Patents Index; Class A25, AN 96-008860, XP002025214 *
DIETZ ET AL: "Zur Problematik der Radiogen-....", HNO, vol. 43, July 1995 (1995-07-01), pages 403 - 13, XP000650803 *
TOGO ET AL: "clinical evaluation of prophylactic intranasal...", MED. MICROBIOL. IMMUNOL., vol. 163, 1977, pages 37 - 44, XP002025211 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291500B2 (en) * 1997-10-22 2001-09-18 Jens Ponikau Methods and materials for treating and preventing inflammation of mucosal tissue
US6555566B2 (en) 1997-10-22 2003-04-29 Mayo Foundation For Medical Education And Research Methods and materials for treating and preventing inflammation of mucosal tissue
EP1744767A2 (fr) * 2004-04-20 2007-01-24 The University of Chicago Systeme d'administration therapeutique comprenant un compose de type peg de poids moleculaire eleve
JP2007533755A (ja) * 2004-04-20 2007-11-22 ザ ユニヴァーシティ オヴ シカゴ 高分子量ｐｅｇ様化合物を含む治療薬送達システム
EP1744767A4 (fr) * 2004-04-20 2008-08-13 Univ Chicago Systeme d'administration therapeutique comprenant un compose de type peg de poids moleculaire eleve

Also Published As

Publication number Publication date
DE19541815A1 (de) 1997-05-15
DE19541815B4 (de) 2008-04-10

Similar Documents

Publication Publication Date Title
DE60109044T2 (de) Arzneimittel zur behandlung der mucositis, stomatitis und des behcetschen syndroms
WO1988010121A1 (fr) Emploi d'un medicament pour traiter l'oeil et support approprie
EP0773022B3 (fr) Composition pharmaceutique pour le traitement de la rhinite, contenant un sympathomimétique et du pantothenol et/ou de l'acide pantothénique
CH662945A5 (de) Ophthalmische loesung.
CA2141056C (fr) Traitement contre les infections dentoalveolaires au moyen de taurolidine et (ou) de taurultam
DE60204584T2 (de) Zusammensetzungen enthaltend eine niedrige konzentration an peroxide zur behandlung von vaginitis
EP0125634A1 (fr) Utilisation d'une substance sécrétolytique pour l'obtention d'un agent contre le ronflement et pour combattre le phénomène de ronflement
CN102159198A (zh) 皮肤感染的局部治疗
EP0285856B1 (fr) Emploi de dihydroergotamine et de ses sels pour le traitement local de troubles trophiques
EP0037488A2 (fr) Composition pharmaceutique pour la guérison des affections inflammatoires et/ou dégénératives et/ou atrophiées des membranes muqueuses
WO2003047604A1 (fr) Utilisation de composes contenant du selenite pour produire un agent a administrer par voie topique ou buccale
CH662734A5 (de) Antischnarchmittel.
DE10208313A1 (de) Ambroxol für die Behandlung von schmerzhaften Zuständen im Mund und Rachenraum
US6488912B1 (en) Treatment of dentoalveolar infections with taurolidine and/or taurultam
DE3610997A1 (de) Ambroxol-nasenspray
EP0450123B1 (fr) Composition pharmaceutique pour application topique contenant du diclofenac-sodium
WO1997017078A1 (fr) Utilisation de polyethyleneglycol pour assurer la prophylaxie ou le traitement d'affections des muqueuses
DE602004011786T2 (de) Taurin bromamin für die inhibierung von pathogenen bakterien und pilzwachstum sowie in einer mikrobiziden zusammensetzung
DE3787274T2 (de) Pharmazeutische Präparate, die eine wässerige Lösung eines Pyranoquinolins enthalten.
DE4300969A1 (fr)
DE4434929A1 (de) Nystatin-Haftsalbe
CH690816A5 (de) Verwendung eines Teil- oder Vollextrates aus nicht fermentierter Camellia sinensis L. zur Herstellung eines Medikamentes, eines Medizinproduktes, eines kosmetischen Präparates oder eines Nahrungsergänzungsproduktes.
DE2426393C3 (de) Gebrauchsfertiges flüssiges Gurgelmittel mit antimikrobieller Wirksamkeit
DE2126204A1 (de) Lysozympraparate
DE2235348A1 (de) Heilmittel zur behandlung der gonorrhoe sowie dessen verwendung

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 97517865

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase